Bristol-myers Squibb Compnay

Zheming Ruan

Lan-Ying Qin

Brian E Fink

Dharmpal S Dodd

Yufen Zhao

Lalgudi S Harikrishnan

Muthoni G Kamau

Christopher Blair Cooper

Libing Chen

Steven J Walker

Jeffrey A Robl

Jun Li

Lawrence G Hamann

Michael A Poss

Joseph Anthony Tino

Robert J Cherney

Scott Hunter Watterson

Rajeev S Bhide

James J Li

David Marcoux

Lyndon A M Cornelius

Qing Shi

Haixia Wang

T G Murali Dhar

James Aaron Balog

Douglas G Batt

Wu Yang

Michael G Yang

Upender Velaparthi

Peter Kinam Park

Zili Xiao

Qingjie Liu

Ashok Vinayak Purandare

David R Tortolani

Emily Charlotte Cherney

John K Dickson

Khehyong Ngu

Anurag S Srivastava

Hua Gong

Hasibur Rahaman

James Neels

Samuel J Bonacorsi, Jr

Arvind Mathur

Dora M Schnur

Wayne David Vaccaro

Robert Joseph Cherney

Brian Edward Fink

Pravin S Shirude

Lyndon AM Cornelius

TG Murali Dhar

Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.

Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

Disclosed are compounds of Formula (I): or stereoisomers, tautomers, or salts thereof, wherein each R is independently H or D. Also disclosed are methods of using such compounds to decrease the levels of IKZF1-4 proteins; and pharmaceutical compositions comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted phenyl oxazolone compounds

The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Cyclic dinucleotides as anticancer agents

The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. 

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. 

Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Qis: (i) Cl, Br, I, &#x2014;CN, &#x2014;CH, or &#x2014;CF; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Rand zero to 1 R; and R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases. 

Bicyclic heteroaryl amine compounds

Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, &#x2014;CN, &#x2014;CH, or &#x2014;CF; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R; Qis pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with Rand R; and R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases. 

Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R, R, Rand Rare defined herein.

Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L, R, R, Rand Rare defined herein.

Trisubstituted heteroaromatic compounds having the structure are provided, wherein

Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators

Growing community of inventors

Dayton, NJ, United States of America

Zheming Ruan